PDF icon Download PDF
Dtsch Med Wochenschr 2001; 126(1/2): 24-29
DOI: 10.1055/s-2001-9888
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Die Behandlung von Risikofaktoren zur Primärprophylaxe zerebraler Ischämien

F. Buggle, A. J. Grau, W. Hacke
  • Neurologische Klinik (Ärztlicher Direktor: Prof. Dr. Werner Hacke) der Universität Heidelberg
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available ateRef
   Permissions and Reprints
Preview

Zerebrovaskuläre Erkrankungen gehören weltweit zu den häufigsten Todesursachen. In Deutschland erkranken etwa 150 000 Einwohner pro Jahr neu an einem Schlaganfall. Zerebrale Ischämien sind die häufigste Ursache frühzeitiger Invalidität. Sie verursachen großes individuelles Leid, die Folgekosten erreichen volkswirtschaftlich relevante Summen [41]. Schlaganfälle können verhindert werden; die hohe Prävalenz und das Wissen um Risikofaktoren prädestinieren diese Erkrankung für präventive Maßnahmen [18]. In dieser Übersichtsarbeit sollen Risikofaktoren für die Entstehung zerebraler Ischämien und ihre Behandlungsmöglichkeiten erörtert werden. Bezüglich der Risikofaktoren für hämorrhagische Infarkte sei auf andere Arbeiten verwiesen [34].

Literatur

  • 1 Alfthan G, Pekkanen J, Jauhiainen M. et al . Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.  Atherosclerosis. 1994;  106 9-19
    Search in Google Scholar
  • 2 Allenberg J, Brandt T, Thron A. Percutane transluminale Angioplastie und Stenting bei Stenosen der A. carotis interna.  Nervenarzt. 1999;  70 314
    Search in Google Scholar
  • 3 American Diabetes Association . Clinical practice recommendations.  Diabetes Care. 1998;  21 1-89 (suppl.1))
    Search in Google Scholar
  • 4 Anderson J L, Muhlestein J B, Carlquist J. et al . Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection.  Circulation. 1999;  99 1540-1547
    Search in Google Scholar
  • 5 Antiplatelet Trialists Collaboration . Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
    Search in Google Scholar
  • 6 Biller J, Feinberg W, Castaldo J. et al . Guidelines for carotid endarterectomy: A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association.  Circulation. 1998;  97 501-509
    Search in Google Scholar
  • 7 Boushey C J, Beresford S A, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes.  JAMA. 1995;  274 1049-1057
    Search in Google Scholar
  • 8 Collins R, Peto R, MacMahon S. et al . Blood pressure, stroke, and coronary heart disease. Part 2, Short term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context.  Lancet. 1990;  335 827-838
    Search in Google Scholar
  • 9 Cromwell J, Bartosch W J, Fiore M C, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy Research.  JAMA. 1997;  278 1759-1766
    Search in Google Scholar
  • 10 Dyken M E, Somers V K, Yamada T, Ren Z Y, Zimmerman M B. Investigating the relationship between stroke and obstructive sleep apnea.  Stroke. 1996;  27 401-407
    Search in Google Scholar
  • 11 European Atrial Fibrillation Trial Study Group . Optimal oral anticoagulattion therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia.  N Engl J Med. 1995;  333 5-10
    Search in Google Scholar
  • 12 Executive Committee for the Asymptomatic Carotid Atherosclerosis Study . Endarterectomy for asymptomatic carotid artery stenosis.  JAMA. 1995;  273 1421-1428
    Search in Google Scholar
  • 13 Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease.  Stroke. 1999;  30 299-305
    Search in Google Scholar
  • 14 Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy.  Lancet. 1999;  353 1586-1587
    Search in Google Scholar
  • 15 Flemming M F, Barry K L, Manwell L B, Johnson K, London R. Brief physician advice for problem drinkers.   JAMA. 1997;  277 1039-1045
    Search in Google Scholar
  • 16 Gillman M W, Cupples L A. et al . Protective effect of fruits and vegetables on development of stroke in men.  JAMA. 1995;  273 1113-1117
    Search in Google Scholar
  • 17 Gupta S, Leatham E W, Carrington D, Mendall M A, Kaski J C, Camm A J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.  Circulation. 1997;  96 404-407
    Search in Google Scholar
  • 18 Gorelick P B, Sacco R L, Smith D B. et al . Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association.  JAMA. 1999;  281 1112-1120
    Search in Google Scholar
  • 19 Gorelick P B, Schneck M, Berglund L F, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke.  Neuroepidemiology. 1997;  16 107-115
    Search in Google Scholar
  • 20 Grau A J, Buggle F, Ziegler C. et al . Association between acute cerebrovascular ischemia and chronic and recurrent infection.  Stroke. 1997;  28 1724-1729
    Search in Google Scholar
  • 21 Hankey G J, Warlow C P. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.  Lancet. 1999;  354 1457-1463
    Search in Google Scholar
  • 22 Jorenby D E, Leischow S J, Nides M A. et al . A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.  N Engl J Med. 1999;  340 685-691
    Search in Google Scholar
  • 23 Kawachi I, Colditz G A, Stampfer M J. et al . Smoking cessation and decreased risk of stroke in women.  JAMA. 1993;  269 232-236
    Search in Google Scholar
  • 24 Kiely D K, Wolf P A, Cupples L A. et al . Physical activity and stroke risk: The Framingham Study.  Am J Epidemiology. 1994;  140 608-620
    Search in Google Scholar
  • 25 Kronmal R A, Hart R G, Manolio T A, Talbert R L, Beauchamp N J, Newman A. Aspirin use and incident stroke in the Cardiovascular Health Study.  Stroke. 1998;  29 887-894
    Search in Google Scholar
  • 26 Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation.  Chest. 1995;  108 352-359 (suppl 4))
    Search in Google Scholar
  • 27 Lee I M, Paffenbarger R S. Physical activity and stroke incidence. The Harvard Alumni Health Study.  Stroke. 1998;  29 2049-2054
    Search in Google Scholar
  • 28 Matchar D B, McCrory D C, Bamen H J, Feussner J R. Medical treatment for stroke prevention.  Annals Int Med. 1994;  121 41-53
    Search in Google Scholar
  • 29 Mathias K, Jäger H, Sahl H, Hennigs S, Gißler H M. Die Endoluminale Therapie der Karotisstenose.  Deutsches Ärzteblatt. 1999;  96 2502-2508
    Search in Google Scholar
  • 30 Messerli F, Grossman E, Goldbourt U. Are beta-blockers efficacous as first-line therapy for hypertension in the elderly? A systematic review.  JAMA. 1998;  279 1903-1907
    Search in Google Scholar
  • 31 Perry I, Refsum H, Morris R, Ebrahim S, Ueland P, Shaper A. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.  Lancet. 1995;  346 1395-1398
    Search in Google Scholar
  • 32 Prystowsky E N, Benson D W Jr, Fuster V. et al . Management of patients with atrial fibrillation. A statement for healthcare professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Aosociafion.  Circulation. 1996;  93 1262-1277
    Search in Google Scholar
  • 33 Report of the Quality Standards Subcommittee of the American Academy of Neurology . Practice parameter: Stroke prevention in patients with nonvalvular atrial fibrillation.  Neurology. 1998;  51 671-673
    Search in Google Scholar
  • 34 Sacco R L, Benjamin E J, Broderick J P. et al . Risk factors.  Panel Stroke. 1997;  28 1507-1517
    Search in Google Scholar
  • 35 Sacks F M, Pfeffer M A, Moye L A. et al . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recunent Events Trial investigators.  N Engl J Med. 1996;  335 1001-1009
    Search in Google Scholar
  • 36 Saikku P, Leinonen M, Mattila K J. et al . Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease an acute myocardial infarction.  Lancet. 1988;  2 (8618) 983-986
    Search in Google Scholar
  • 37 Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study.  Lancet. 1994;  344 1383-1389
    Search in Google Scholar
  • 38 SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.   JAMA. 1991;  265 3255-3264
    Search in Google Scholar
  • 39 Sievert H, Pfeil W, Bösenberg I, Spies H, Theis R, Beykirch K F. Primäre Stent-Implantation in der Arteria carotis interna.  Dtsch med Wschr. 1999;  124 1262-1266
    Search in Google Scholar
  • 40 Steering Committee of the Physicians Health Study Research Group . Final report on the aspirin component of the ongoing Physicians Health Study.  N Engl J Med. 1989;  321 129-135
    Search in Google Scholar
  • 41 Taylor T N, Davis P H, Tomer J C, Holmes J, Meyer J W, Jacobson M F. Lifetime cost of stroke in the United States.  Stroke. 1996;  27 1459-1466
    Search in Google Scholar
  • 42 The Atrial Fibrillation Investigators . The efficacy of aspirin in patients with atrial fibrillation: Analysis of pooled data from 3 randomized trials.  Arch Intern Med. 1997;  157 1237-1240
    Search in Google Scholar
  • 43 The Diabetes Control and Complications Trial Group . Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.  Am J Cardiol. 1995;  75 894-903
    Search in Google Scholar
  • 44 The Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure . The 6th report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.  Arch Intern Med. 1997;  157 2413-2446
    Search in Google Scholar
  • 45 The National Cholesterol Education Program (NCEP) Expert Panel . Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel in Adults (Adult Treatment Panel II).  JAMA. 1993;  269 3015-3023
    Search in Google Scholar
  • 46 UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33.  Lancet. 1998;  352 837-853
    Search in Google Scholar
  • 47 UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascuiar and microvascular complications in type 2 diabetes: UKPDS 38.  BMJ. 1998;  317 703-713
    Search in Google Scholar
  • 48 Verhoef P, Hennekens C H, Malinow M R, Kok F J, Willett W C, Stampfer M J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.  Stroke. 1994;  25 1924-1930
    Search in Google Scholar
  • 49 Wolf P A, Abbott R D, Kannel W B. Atrial Fibrillation as an independent risk factor for stroke: The Framingham Study.  Stroke. 1991;  22 983-988
    Search in Google Scholar
  • 50 Wolf P A, DAgostino R B, Kannel W B, Bonita R  Belanger AJ. Cigarette smoking as a risk factor for stroke: The Framingliam Study.  JAMA. 1998;  259 1025-1029
    Search in Google Scholar

Korrespondenz

Dr. med. Florian Buggle

Neurologische Klinik

Im Neuenheimer Feld 400

69120 Heidelberg

Phone: 06221/567504

Fax: 06221/565451

Email: Florian_Buggle@med.uni-heidelberg.de